Key Industry Challenges Take Center Stage at PDA Aseptic Manufacturing Excellence Conference 2026

Melbourne event explores evolving regulatory expectations, quality risk management and the technologies shaping the future of sterile manufacturing

From evolving contamination control strategies and Annex 1 implementation to artificial intelligence-enabled environmental monitoring and the future of airflow science, the challenges facing sterile manufacturers continue to grow in complexity. The PDA Aseptic Manufacturing Excellence Conference 2026, taking place on 14-15 October 2026 at Pullman East Melbourne, has been designed to help industry professionals navigate this changing landscape through practical case studies, regulatory perspectives, and emerging best practices.

(Image: PDA)

Co-organized by the PDA Asia Pacific and PDA Australia Chapter, the conference will gather professionals from pharmaceutical, biotechnology, quality, regulatory, engineering, microbiology, validation, and manufacturing disciplines for two days of focused discussion on the operational realities of aseptic manufacturing.

The program reflects a significant shift occurring across the industry. While compliance remains a critical objective, organizations are increasingly seeking ways to build contamination control into every stage of the product lifecycle, leverage data more effectively, and prepare for future regulatory expectations.

Regulatory Expectations Continue to Drive Industry Transformation

The conference opens with a regulatory plenary focused on sterile manufacturing compliance and contamination control governance.

Invited representatives from the Therapeutic Goods Administration (TGA) will discuss current GMP inspection themes and emerging areas of regulatory interest, providing attendees with insights into the expectations shaping sterile manufacturing operations in Australia and globally.

Complementing this regulatory perspective, Wei Xia Ang, PhD, Senior Regulatory Compliance Lead at Cytiva and former regulator with Singapore’s Health Sciences Authority (HSA), will examine the evolution of Contamination Control Strategies (CCS).

Rather than treating CCS as a standalone compliance document, organizations are increasingly expected to implement contamination control as an integrated quality management system. The session will explore how Environmental Monitoring (EM), Aseptic Process Simulation (APS), deviations, CAPA, change control, and Quality Risk Management can work together as a unified contamination control framework.

As regulators continue to emphasize data-driven decision-making and lifecycle approaches to contamination control, these discussions are expected to provide valuable context for manufacturers preparing for future inspections and evolving global expectations.

Practical Solutions for Modern Isolator Operations

One of the most anticipated streams of the conference focuses on isolator technology and the operational challenges associated with modern aseptic processing.

Despite widespread adoption of isolator systems, questions remain regarding qualification strategies, filtration approaches, glove integrity testing, environmental monitoring requirements, and the interpretation of expectations developed before many current technologies existed.

The session "Beyond Containment: The Operational Reality of Isolator Technology" examines these topics through a combination of expert presentations and interactive discussion.

A highlight of the stream will be "Isolators: The Great Debate," which brings together experts from Cytiva, ValSource, Lachman Consultants, and SKAN to discuss areas where regulatory interpretation, scientific understanding, and operational realities do not always align.

Topics include first-air concepts, open-door practices, bio-fluorescent particle counting technologies, settle plate usage, and the broader challenge of balancing compliance expectations with scientific, risk-based decision making.

The format is designed to encourage candid discussion and practical perspectives that attendees can apply within their own facilities.

Preparing Facilities for Long-Term Compliance and Performance

As pharmaceutical companies invest in new facilities, technologies, and manufacturing capabilities, the relationship between facility design and contamination control continues to receive growing attention.

The conference includes a dedicated stream focused on operational readiness and contamination control by design.

Speakers will examine how organizations can incorporate contamination control considerations during project planning, facility design, equipment selection, commissioning, and qualification activities instead of relying on retrospective remediation after construction is complete.

Sessions from CAI and EngCOR will explore modern project delivery frameworks that integrate operational readiness throughout the project lifecycle.

A Pfizer Melbourne case study will demonstrate how early planning and structured readiness programs can improve project execution, reduce compliance risk, and support successful manufacturing start-up activities.

The growing emphasis on operational readiness reflects broader industry recognition that compliance outcomes are heavily influenced by decisions made long before manufacturing operations begin.

Addressing Persistent Compliance Challenges

Despite significant advances in quality systems and regulatory oversight, many of the most frequently observed inspection findings remain remarkably consistent across organizations and regions.

Several conference sessions address recurring challenges surrounding investigations, root cause determination, and corrective and preventive actions.

Drawing on global inspection experience and perspectives from former inspectors, speakers will examine why incomplete investigations, weak root cause analysis, and ineffective CAPA programs continue to appear among the industry’s most common deficiencies.

Attendees will gain practical insights into investigation methodologies, sustainable CAPA design, and approaches for improving organizational learning from deviations and quality events.

Interactive workshops, including the popular "Would You Release This Batch?" session and case-based investigation exercises, will encourage participants to evaluate evidence, challenge assumptions, and explore how decision-making evolves as new information becomes available.

These sessions emphasize critical thinking and scientific reasoning as essential components of modern quality systems.

Quality Risk Management Takes Center Stage

As contamination control programs continue to mature, Quality Risk Management has become a central theme across pharmaceutical operations.

The conference includes several sessions focused on risk-based approaches to contamination control, including presentations on the newly published PDA/ANSI Standard 03-2025: Standard Practice for Quality Risk Management of Aseptic Processes.

The standard introduces a more holistic framework for evaluating contamination risk throughout the aseptic manufacturing lifecycle and offers an alternative perspective to traditional scoring-based risk assessment tools.

Additional presentations will examine the expanding relationship between sterile product manufacturers and suppliers of sterile primary packaging components, exploring how contamination control responsibilities intersect across increasingly complex pharmaceutical supply chains.

Collectively, these sessions highlight an industry movement toward broader, evidence-based approaches to contamination control and product quality assurance.

(Image: PDA)

Environmental Monitoring Enters a New Era

Among the most future-focused topics featured at the conference is the evolution of environmental monitoring through advanced analytics, automation, artificial intelligence, and emerging microbiological technologies.

Speakers will explore how AI-supported systems can improve access to manufacturing data, accelerate contamination investigations, and help organizations identify patterns within environmental monitoring programs more effectively.

Sessions will cover practical applications including:

• Natural-language interrogation of contamination datasets
• AI-powered microbiology workflows
• Automated culture plate reading
• Data integrity considerations
• Validation principles for AI systems
• Risk-based environmental monitoring strategies

In parallel, experts will review current and future USP documentary and reference standards influencing environmental monitoring expectations across the pharmaceutical industry.

Together, these presentations offer a forward-looking perspective on how technology, automation, and harmonized scientific standards may redefine contamination control practices over the coming years.

(Image: PDA)

Looking Beyond Today’s Requirements

The conference concludes by examining what may come next for sterile manufacturing.

The closing plenary focuses on anticipated PIC/S developments and emerging approaches to airflow visualization.

Edward C. Tidswell, PhD, Executive Director QA at MSD, will discuss the growing role of computational fluid dynamics (CFD) in understanding airflow behavior and supporting contamination-control decision-making.

As regulatory scrutiny of traditional airflow visualization practices continues, CFD has the potential to provide more objective, data-rich assessments that complement existing approaches.

The session will explore how digital modeling technologies, real-time data integration, and future standards may reshape the industry’s understanding of airflow performance and environmental monitoring.

Together with regulatory perspectives on anticipated PIC/S updates, the closing plenary offers attendees insight into the trends likely to influence sterile manufacturing in the years ahead.

Beyond the Conference

Conference participants will be eligible to attend a complimentary PDA Site Visit at Pfizer Australia and Pure Solutions Australia on 16 October 2026. Available exclusively to conference attendees, the visit will provide firsthand exposure to pharmaceutical manufacturing and support operations. Attendance is limited and allocated on a first-come, first-served basis.

Source: PDA